Read + Share
Li S, Peng L, Tan C, Zeng X, et al. Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for
advanced gastric or gastro-oesophageal cancer in China. PLoS One 2020;15:e0232240.
PMID: 32379763
|
 |
|
Li S, Peng L, Tan C, Zeng X, et al. Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for
advanced gastric or gastro-oesophageal cancer in China. PLoS One 2020;15:e0232240.
PMID: 32379763
|
|
|
|